Chen MH, Yang WLR, Lin KT, Liu CH, Liu YW, Huang KW, Chang PMH, Lai JM, Hsu CN, Chao KM, Kao CY, Huang CYF
PLoS ONE - vol. 6 (2011)
Hepatocellular carcinoma (HCC) is an aggressive tumor with a poor prognosis. Currently, only sorafenib is approved by the FDA for advanced HCC treatment; therefore, there is an urgent need to discover candidate therapeutic drugs for HCC. We hypothesized that if a drug signature could reverse, at least in part, the gene expression signature of HCC, […]